Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Drugs in R&D|January 19, 2021
Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid TumoursMarit A C Vermunt, Vincent A de Weger, Julie M Janssen, et al.
Bioanalysis|December 15, 2015
Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBSRemy B Verheijen, Sander Bins, Bas Thijssen, et al.
Cancers|November 27, 2021
Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue SarcomaLaura Molenaar-Kuijsten, Milan van Meekeren, Remy B Verheijen, et al.
The Oncologist|December 9, 2020
Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic CancerEmilie M J van Brummelen, Sanne Huijberts, Carla van Herpen, et al.
Clinical Pharmacokinetics|February 6, 2020
Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer PatientsStefanie L Groenland, Ruben A G van Eerden, Remy B Verheijen, et al.
Cancer Reports (Hoboken, N.J.)|March 12, 2021
ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib studyMarit A C Vermunt, Debbie G J Robbrecht, Lot A Devriese, et al.
European Journal of Cancer (Oxford, England : 1990)|October 15, 2017
A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavirVincent A de Weger, Frederik E Stuurman, Jeroen J M A Hendrikx, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2019
A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with RitonavirVincent A de Weger, Frederik E Stuurman, Stijn L W Koolen, et al.
Cancer Chemotherapy and Pharmacology|April 11, 2020
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancerSanne C F A Huijberts, Robin M J M van Geel, Emilie M J van Brummelen, et al.
British Journal of Cancer|March 10, 2020
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancerRobin M J M van Geel, Emilie M J van Brummelen, Ferry A L M Eskens, et al.
Pageof 2